Upcoming Patent Cliffs
Where the next $300B of revenue meets generic / biosimilar entry.
A live view of upcoming patent cliffs — by molecule, sponsor, indication and revenue-at-risk through 2030.
"Which cliffs matter most for our portfolio defense and BD strategy?"
The 2026–2030 patent cliff cycle puts ~$300B of pharma revenue at risk. Cliff timing, geography and biosimilar entry shape both defender and challenger plays.
The 2026–2030 patent cliff is the largest in pharma history. Live cliff tracking with revenue-at-risk modeling powers defender lifecycle plays and challenger generic/biosimilar entries alike.
What we’re seeing in the data.
$300B+ revenue at risk by 2030
Driving record M&A pace.
Biologics dominate the cliff
Biosimilar entry pace varies by molecule.
Geography shapes cliff timing
EU often loses exclusivity earlier than US.
How to think about it.
-
01
Map cliff calendar
Molecule × geography.
-
02
Score revenue at risk
Current sales × erosion curve.
-
03
Identify defender plays
Lifecycle, formulation, combo.
-
04
Surface challenger opportunities
Generic / biosimilar / new entrant.
What separates a good answer from a defensible one.
Settlements can extend exclusivity.
Defender strategy.
Manufacturing constrains entry.
Where the signal comes from.
Common questions.
How accurate is cliff timing?
± 6 months due to litigation and settlement variability.
Defenders win or lose?
Lifecycle and combo strategies typically retain 40–70% of pre-cliff revenue.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist